文献速递肝病

组蛋白甲基转移酶Suv39h1调控肝星状细胞活化并在肝纤维化中可靶向干预

Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
PubMed 文献 · Gut · 2024-04-05

本研究探讨赖氨酸甲基转移酶Suv39h1在肝星状细胞向肌成纤维细胞转化及肝纤维化中的作用。通过肝星状细胞或肌成纤维细胞特异性Suv39h1敲除小鼠及CCl4注射或胆管结扎诱导的肝纤维化模型,发现Suv39h1表达上调,敲低或敲除可改善肝纤维化;小分子化合物chaetocin抑制Suv39h1可减轻细胞转化和小鼠肝纤维化。机制上Suv39h1结合HMOX1启动子抑制其转录,HMOX1通过调节视黄醇稳态发挥作用,肌成纤维细胞特异性过表达HMOX1在预防和治疗方案中均减轻肝纤维化。

要点

  • Suv39h1在肝星状细胞向肌成纤维细胞转化中普遍上调,敲低可阻断该转化。
  • 肝星状细胞或肌成纤维细胞特异性敲除Suv39h1可改善小鼠肝纤维化。
  • 小分子化合物chaetocin抑制Suv39h1可减轻细胞转化和小鼠肝纤维化。

核心结论

  • Suv39h1在肝纤维化中具有先前未认识的作用,并为其在肝硬化干预中的可靶向性提供了概念验证。

研究设计与样本

  • 通过将Suv39h1 f/f小鼠与Lrat-Cre小鼠或Postn-CreERT2小鼠杂交,实现肝星状细胞特异性或肌成纤维细胞特异性Suv39h1缺失。
  • 通过CCl4注射或胆管结扎诱导肝纤维化。

主要发现

  • Suv39h1表达在不同细胞和动物肝纤维化模型及人肝硬化肝组织中于肝星状细胞向肌成纤维细胞转化过程中普遍上调。
  • Suv39h1敲低在体外阻断肝星状细胞向肌成纤维细胞转化。
  • 肝星状细胞特异性或肌成纤维细胞特异性Suv39h1缺失改善小鼠肝纤维化。
  • 小分子化合物chaetocin抑制Suv39h1在细胞培养中减弱肝星状细胞向肌成纤维细胞转化并在小鼠中减轻肝纤维化。
  • Suv39h1结合血红素加氧酶1(HMOX1)启动子并抑制HMOX1转录,HMOX1耗竭减弱Suv39h1抑制对体外肝星状细胞向肌成纤维细胞转化和体内肝纤维化的效果。

关键数值与推荐

  • 转录组分析显示HMOX1可能通过调节视黄醇稳态参与肝星状细胞向肌成纤维细胞转化。
  • 肌成纤维细胞特异性HMOX1过表达在预防方案和治疗方案中均减轻肝纤维化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Liver fibrosis is a prelude to a host of end-stage liver diseases. Hepatic stellate cells (HSCs), switching from a quiescent state to myofibroblasts, are the major source for excessive production of extracellular matrix proteins. In the present study, we investigated the role of Suv39h1, a lysine methyltransferase, in HSC-myofibroblast transition and the implication in liver fibrosis. DESIGN: HSC-specific or myofibroblast-specific Suv39h1 deletion was achieved by crossbreeding the Suv39h1 f/f mice to the Lrat-Cre mice or the Postn-CreERT2 mice. Liver fibrosis was induced by CCl4 injection or bile duct ligation. RESULTS: We report that Suv39h1 expression was universally upregulated during HSC-myofibroblast transition in different cell and animal models of liver fibrosis and in human cirrhotic liver tissues. Consistently, Suv39h1 knockdown blocked HSC-myofibroblast transition in vitro. HSC-specific or myofibroblast-specific deletion of Suv39h1 ameliorated liver fibrosis in mice. More importantly, Suv39h1 inhibition by a small-molecule compound chaetocin dampened HSC-myofibroblast transition in cell culture and mitigated liver fibrosis in mice. Mechanistically, Suv39h1 bound to the promoter of heme oxygenase 1 (HMOX1) and repressed HMOX1 transcription. HMOX1 depletion blunted the effects of Suv39h1 inhibition on HSC-myofibroblast transition in vitro and liver fibrosis in vivo. Transcriptomic analysis revealed that HMOX1 might contribute to HSC-myofibroblast transition by modulating retinol homeostasis. Finally, myofibroblast-specific HMOX1 overexpression attenuated liver fibrosis in both a preventive scheme and a therapeutic scheme. CONCLUSIONS: Our data demonstrate a previously unrecognised role for Suv39h1 in liver fibrosis and offer proof-of-concept of its targetability in the intervention of cirrhosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kong M, Zhou J, Kang A, et al. Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis. Gut. 2024. PMID: 38176898. doi:10.1136/gutjnl-2023-329671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。